Wanner C, Zimmermann J, Schwedler S, et al. Inflammation and cardiovascular risk in dialysis patients[J]. Kidney Int, 2002, 18(8): 1452-1455.
[2]
Dimitrow PP, Jawie？ M. Anti-inflammatory effect of atorvastatin in patients with aortic sclerosis or mild aortic stenosis independent of hypercholesterolemia[J]. Pharmacological Rep, 2010, 62(6): 1250-1254.
[3]
M？rz W, Genser B, Drechsler C, et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis[J]. Clin J Am Soc Nephrol, 2011, 6(6): 1316-1325.
[4]
Her AY, Kim JY, Kang SM, et al. Effects of atorvastatin 20 mg,rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism[J]. J Cardiovasc Pharmacol Ther, 2010, 15(2): 167-174.
[5]
Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency[J]. Circulation, 2003, 107(1): 87-92.
[6]
Recio-mayoral A, Banerjee D, Streather C, et al. Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease:a cross-sectional study of predialysis, dialysis and kidney-transplantation patients[J]. Atherosclerosis, 2011, 216(2): 446-451.
[7]
Zyga S, Christopoulou G, Malliarou M. Malnutrition-inflammation-atherosclerosis syndrome in patients with end-stage renal disease[J]. J Ren Care, 2011, 37(1): 12-15.
[8]
Michel C, Giuseppe L, Martina M, et al. Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis[J]. Nephrol Dial Transplant, 2008, 23(9): 2879-2883.
[9]
Ross R. Atrheroselerosis-an inflammatory disease[J]. N Engl J Med, 1999, 340(2): 115-126.
[10]
王海燕. 肾脏病学[M]. 3版. 北京: 人民卫生出版社, 2008: 1886-1892.
[11]
Goldsmith D, Covic AC. Jupiter or Aurora Micro-inflammation and dyslipidaemia: twin targets for statin therapy in CKD[J]. Int Urol Nephrol, 2010, 42(1): 133-136.
Burmeister JE, Miltersteiner DR, Campos BM. Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein[J]. J Nephrol, 2009, 22(1): 83-89.
[15]
Verma A, Ranganna KM, Reddy RS, et al. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease[J]. Am J Cardiol, 2005, 96(9): 1290-1292.
[16]
Gómez-García A, Martínez Torres G, Ortega-Pierres LE, et al. Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia[J]. Rev Esp Cardiol, 2007, 60(12): 1242-1249.
[17]
Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J]. N Engl J Med, 2008, 359(21): 2195-2207.
[18]
Qu HY, Xiao YW, Jiang GH, et al. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia[J]. Pharm Res, 2009, 26(4): 958-964.
